"Tretinoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).
| Descriptor ID |
D014212
|
| MeSH Number(s) |
D02.455.326.271.665.202.495.818.500 D02.455.426.392.368.367.379.249.700.860.500 D02.455.849.131.495.818.800 D23.767.261.700.780
|
| Concept/Terms |
Tretinoin- Tretinoin
- Retinoic Acid
- Acid, Retinoic
- Vitamin A Acid
- Acid, Vitamin A
- all-trans-Retinoic Acid
- Acid, all-trans-Retinoic
- all trans Retinoic Acid
- trans-Retinoic Acid
- Acid, trans-Retinoic
- trans Retinoic Acid
|
Below are MeSH descriptors whose meaning is more general than "Tretinoin".
Below are MeSH descriptors whose meaning is more specific than "Tretinoin".
This graph shows the total number of publications written about "Tretinoin" by people in this website by year, and whether "Tretinoin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 0 | 1 | 1 |
| 1997 | 3 | 1 | 4 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 1 | 4 |
| 2003 | 4 | 2 | 6 |
| 2004 | 0 | 3 | 3 |
| 2005 | 3 | 2 | 5 |
| 2006 | 2 | 1 | 3 |
| 2008 | 1 | 3 | 4 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 4 | 7 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 2 | 5 |
| 2013 | 1 | 3 | 4 |
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 2 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tretinoin" by people in Profiles.
-
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer. 2025 Jan 01; 131(1):e35662.
-
Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):375-381.
-
Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients. Leuk Lymphoma. 2024 Mar; 65(3):378-382.
-
Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study. Signal Transduct Target Ther. 2023 09 27; 8(1):368.
-
A novel retinoic acid receptor-? agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment. Sci Rep. 2023 09 09; 13(1):14907.
-
Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells. Cancer Res. 2023 07 14; 83(14):2387-2404.
-
A global study for acute myeloid leukemia with RARG rearrangement. Blood Adv. 2023 07 11; 7(13):2972-2982.
-
Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition. Cancer Res. 2022 09 02; 82(17):3158-3171.
-
[Acute promyelocytic leukemia complicated with central nervous system involvement successfully treated with all-trans retinoic acid via nasogastric tube]. Rinsho Ketsueki. 2022; 63(1):26-30.
-
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675.